Human recombinant lactoferrin for sepsis: Too good to be true?

Critical Care Medicine

Volumn 41, Issue 3, 2013, Pages 908-909

  McCulloh, Russell ^a   Opal, Steven M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Clinical trials in sepsis; Lactoferrin; Septic shock

Indexed keywords

PLACEBO; TALACTOFERRIN;

ANTIMICROBIAL ACTIVITY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; INFLAMMATION; LUNG NON SMALL CELL CANCER; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK REDUCTION; SEPSIS;

FEMALE; HUMANS; LACTOFERRIN; MALE; SEPSIS;

EID: 84874916086     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182770fd6     Document Type: Editorial

References (14)

1. Guntupalli K, Dean N, Morris PE et al: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis. Crit Care Med 2013; 41:706-716
2. Levay PF, Viljoen M: Lactoferrin: A general review. Haematologica 1995; 80:252-267
3. Anderson BF, Baker HM, Norris GE, et al.: Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8 A resolution. J Mol Biol 1989; 209:711-734
4. Legrand D, Elass E, Carpentier M, et al.: Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol 2006; 84:282-290
5. Portelli J, Gordon A, May J T: Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro. J Med Microbiol 1998; 47:1015-1018
6. Legrand D, Elass E, Carpentier M, et al.: Lactoferrin: A modulator of immune and inflammatory responses. Cell Mol Life Sci 2005; 62:2549-2559
7. de la Rosa G, Yang D, Tewary P, et al.: Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol 2008; 180:6868-6876
8. Appelmelk BJ, An YQ, Thijs BG, et al.: Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Infect Immun 1994; 62:3564-3567
9. Spadaro M, Caorsi C, Ceruti P, et al.: Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008; 22:2747-2757
10. Edde L, Hipolito RB, Hwang FF, et al.: Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 2001; 281:G1140-G1150
11. Varadhachary A, Wolf JS, Petrak K, et al.: Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 2004; 111:398-403
12. Manzoni P, Rinaldi M, Cattani S, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology: Bovine lactoferrin supplementation for prevention of lateonset sepsis in very low-birth-weight neonates: A randomized trial. JAMA 2009; 302:1421-1428
13. Manzoni P, Stolfi I, Messner H, et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections - the Italian Society of Neonatology: Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: A randomized controlled trial. Pediatrics 2012; 129:116-123
14. Pierrakos C, Vincent J L: Sepsis biomarkers: A review. Crit Care 2010; 14:R15